- Camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma failing first-line therapy: An open-label, single-arm, phase II studyDing, X.; Zhang, W.; You, R.; Zou, X.; Wang, Z.; Ouyang, Y-F.; Liu, Y-L.; Peng, L.; You-Ping, L.; Duan, C-Y.; Yang, Q.; Lin, C.; Yulong, X.; Chen, S-Y.; Gu, C-M.; Huang, P. Y.; Hua, Y.; Chen, M.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022-09-09 To 2022-09-13.
- Camrelizumab plus famitinib as first-line treatment in advanced NSCLC patients with PD-L1 TPS ≥1%: A report from a multicenter, open-label, phase II basket trialRen, S.; Wang, X.; Han, B.; Pan, Y.; Zhao, J.; Cheng, Y.; Hu, S.; Liu, T.; Li, Y.; Cheng, Y.; Feng, J.; Yi, S.; Gu, S.; Gao, S.; Luo, Y.; Liu, Y.; Liu, C.; Duan, H.; Zhou, C.; Fan, J.
- Camrelizumab as neoadjuvant, first- or later-line treatment for non-small cell lung cancer (NSCLC): A retrospective real-world study (CTONG2004)Xu, C.; Chen, Q.; Zhou, C.; Wu, L.; Li, W.; Zhang, H.; Li, Y.; Xu, F.; Xiong, J.; Wang, Q.; Zhang, H.; Jiang, Y.; Yin, H.; Wu, Q.; Dai, Q.; Hu, J.; Chen, J.; Zhang, J.; Wu, G.; Wu, Y-L.ESMO Immuno-Oncology Congres, ELECTR NETWORK, 2021-12-08 To 2021-12-11.被引 2
会议论文
Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma: Data from an open-label, multicenter phase II basket study.
1被引10阅读
